Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
about
Trabectedin for Soft Tissue Sarcoma: Current Status and Future PerspectivesThe evolution of systemic therapy in sarcoma.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Choline phosphate cytidylyltransferase-α is a novel antigen detected by the anti-ERCC1 antibody 8F1 with biomarker value in patients with lung and head and neck squamous cell carcinomas.Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence.Expression of XPG protein in the development, progression and prognosis of gastric cancer.Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patientsAdvances in sarcoma genomics and new therapeutic targets.BRCA2 is needed for both repair and cell cycle arrest in mammalian cells exposed to S23906, an anticancer monofunctional DNA binder.ERCC1 intron 1 was associated with breast cancer risk.Expression of XPG protein in human normal and tumor tissues.Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.Prolonged response to trabectedin in a heavily pretreated patient with metastatic endometrial carcinoma: A case report and literature review.BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling.Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer.Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomasSystemic management strategies for metastatic soft tissue sarcoma.Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma.Biology of ovarian cancer and trabectedin mechanism of action.Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.Pharmacological treatment for uterine leiomyosarcomas.Unique features of trabectedin mechanism of action.Hallmarks of hyperthermia in driving the future of clinical hyperthermia as targeted therapy: translation into clinical application.Trabectedin is a promising antitumour agent for synovial sarcoma.Hyperthermia adds to trabectedin effectiveness and thermal enhancement is associated with BRCA2 degradation and impairment of DNA homologous recombination repair.Trabectedin for the treatment of soft tissue sarcomas.Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients treated in a French institution.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse modelDiagnostic and prognostic values of the mRNA expression of excision repair cross-complementation enzymes in hepatitis B virus-related hepatocellular carcinoma
P2860
Q26745502-03814380-8D06-4760-9E48-4C52E74CA3F0Q33274710-2C49B758-8947-4ADD-B71C-5A75192E881EQ33617922-B07E422B-1800-45E2-A768-A125E080FDE6Q33717695-8E970AA2-9C76-4BB3-AC6B-1C9E052C5B3BQ33921802-1F17DF47-583A-48C4-876B-3E05E7783C09Q34277562-54852B11-E650-49B1-89CA-4D379644FEA2Q34674564-1A76E3B1-BA09-4E75-9864-F6916523610CQ35098302-DA87ABE5-AD25-4D91-952C-74FCBAC4C845Q35993346-22BBD52A-03E8-4BD8-A510-EF2328CAF183Q36188973-C2D448FD-F44A-4D8F-A753-E634ACFEB187Q36286297-536F9BA4-CF2B-4AB1-A8DC-AA8B32998212Q36529982-C75AA7B7-2583-4E1B-BF36-E7B05B169AD1Q37295535-38C71AC7-727B-4BB4-B3CC-C20711C4C580Q37387282-722E7637-5869-43B1-B01D-9C9F7B0BCD03Q37396876-853AFD84-B539-4BAF-8AD2-71E28463315BQ37622701-178E4312-D4B0-48EF-A72A-4C6CFABAB185Q37747771-DFDE200A-CEF1-4943-BBF9-112FA19A2CD2Q37950516-E274D06D-CBF3-4FA1-8E0E-97A9ABF35F4EQ37969213-69030EC9-1EEC-40F3-8BCA-369721624E64Q38160257-B54A2FDE-6086-4CA8-8232-503BC3A80CFDQ38206366-A105B969-5016-4994-9ADF-BE571AFA9237Q38270671-7A143E5A-B283-4C91-8EF0-8FFEB5375F4FQ38669051-3C59B319-1801-4332-A081-53447BBED7B7Q38709493-C67A74B3-DD6E-4F33-BE6E-9A6C155F9DC4Q38778290-4A93DA4E-3180-4A39-8314-2F8AD348A6C9Q38789729-88DB0143-6DDF-4608-8C3A-3F5148763EEEQ38872192-4B269533-814F-423B-80C2-7E27AD0C1EA3Q39480148-A396ADB7-AEC7-4E31-9ADB-4CC45BAEDADAQ41105379-493B3F5D-6A8C-4B01-9AC3-909295E4F41FQ55011609-63FDAD79-1867-4D2F-B0F0-4CDCB02CEED8Q58736789-15C5D2B5-653E-4A4D-BE4B-1B6B17A86553Q59135049-EB02DA85-6CBA-4290-9BC2-60763CDE16F4
P2860
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Predictive impact of DNA repai ...... rospective multicentric study.
@en
Predictive impact of DNA repai ...... rospective multicentric study.
@nl
type
label
Predictive impact of DNA repai ...... rospective multicentric study.
@en
Predictive impact of DNA repai ...... rospective multicentric study.
@nl
prefLabel
Predictive impact of DNA repai ...... rospective multicentric study.
@en
Predictive impact of DNA repai ...... rospective multicentric study.
@nl
P2093
P50
P1476
Predictive impact of DNA repai ...... rospective multicentric study.
@en
P2093
A Le Cesne
J C Tercero
P Schöffski
P304
P356
10.1016/J.EJCA.2011.01.016
P577
2011-03-04T00:00:00Z